An interventional study of HIIT-training in Microvascular Disease, Microvascular Complications and Dementia, sponsored by University Hospital Bispebjerg and Frederiksberg. Active, not recruiting at 1 site in Denmark. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by University Hospital Bispebjerg and Frederiksberg · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Dementia with a site in Denmark — 6 open to participants now, 12 under way, 1 of them phase 3. Dementia · Denmark.
Among the 30 studies in Dementia with a site in Denmark, this one is the 16th largest by enrollment of the 21 interventional ones that give a count, is one of 6 that started in 2025, is one of 10 with no phase, reaches primary completion later than 7 of the 11 other live ones, and was the 30th registered.
2,376 studies on the registry are indexed under Dementia; 573 are open to participants now.
Browse Dementia studies →6 of the 30 studies in Dementia with a site in Denmark are open now. Recruiting first, the newest first:
Aarhus University Hospital · Sites in Denmark, Germany, Norway and 2 more countries
Ages 50+
University of Southern Denmark · Sites in Denmark
Ages 65+
Aarhus University Hospital · Sites in Denmark
Ages 60+
Zealand University Hospital · Sites in Denmark
Ages 50+ · Healthy volunteers
Center for Clinical Research and Prevention · Sites in Denmark
Ages 18+ · Healthy volunteers
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 382 Dementia studies recruiting now, 243 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 163 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 5 · Phase 4 2
First in 2003; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 90 across 1,762 interventional studies indexed under Dementia.
Median enrollment 339 across the 21 interventional studies, 140 across the 9 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 30 have an industry lead sponsor. The 10 most frequent:
University Hospital Bispebjerg and Frederiksberg is the lead sponsor of 70 studies on the registry; 17 are open to participants now.
University Hospital Bispebjerg and Frederiksberg has 3 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
3 of the studies in Dementia with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06624267University Hospital Bispebjerg and FrederiksbergTest of Reproducibility of [15O]H20-PET Assessment of Brain Perfusion | 2027-01 |
| NCT06451692University of Southern DenmarkPrioritising Patient Medication Review: Hospitals Reaching Out | 2027-01-01 |
| NCT07741526Arctic TherapeuticsSafety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD) | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Dementia with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In the aging population, ischemic heart disease, stroke and dementia are increasingly prevalent. Diagnosis and treatment of the former two i.e., large-vessel coronary heart disease and endovascular thrombectomy of the brain in relation to stroke have improved significantly. Yet, the majority of elderly patients with ischemic heart disease do not have large-vessel heart disease and it seems that small vessel disease (SVD) may explain a large fraction of these cases as well as the cardiovascular morbidity in the elderly. Hence, the current development in diagnostics and treatments of ischemic heart disease does not address the most common subtype of ischemic disease seen in elderly patients.It has been suggested that SVD is part of a multisystem disorder and several systematic reviews have addressed the hypothesis of a potential link between small vessel disease of the heart, brain, and kidneys. Cerebral SVD is prevalent in the aging population causing cognitive impairment, dementia, and an increased risk of stroke, and cerebral hypoperfusion is an acknowledged cause of vascular dementia and a possible cause of Alzheimer's disease. Further, cognitive impairment within multiple cognitive domains is highly prevalent in heart failure and is associated to an increased risk of dementia. The link between heart failure and dementia may be due to multisystem SVD, although a direct link between the two is possible.Among other known risk factors such as age, hypertension, and female sex, diabetes is a major cause of SVD and is linked to coronary heart disease as well as cognitive impairment. The diagnosis of cerebral SVD relies on MRI detecting infarctions, haemorrhages, microbleeds and ischemic white matter changes, i.e. Fazekas score. In contrast, perfusion PET is used to image myocardial perfusion in patients with coronary SVD; and coronary SVD is recognized as a part of the pathophysiology in angina, coronary artery disease, and heart failure. Perfusion PET before and after adenosine-induced vasodilation allows for measuring, the myocardial flow reserve (MFR), i.e. perfusion capacity, which in the absence of regional perfusion defects, is a measure of coronary SVD. Prof. Eva Prescott have recently shown that reduced MFR obtained by 82Rb PET is a strong predictor of future microvascular events and all-cause mortality.Exercise is well known to improve cognitive health but professor Carl-Johan Boraxbekk has shown that the effect on cognitive performance may be dependent on the initial cerebrovascular status, as patients with moderate to severe white matter changes did not improve after a 6 months physical activation intervention in contrast to patients with mild changes. Yet, it is possible to improve brain function in diabetic patients through either dietary or exercise interventions. Systemic SVD is measured as cerebral SVD (reduced brain perfusion during acetazolamide-induced vasodilation) and coronary SVD (reduced heart perfusion during adenosine-induced vasodilation). The researchers anticipate that patients with type 2 dabetes have reduced perfusion capacity of the brain and heart correlating to reduced cognition and cardiorespiratory fitness (VO2-max). Therefore we wish to see if we can improve both CBF and cognitive performance by improving VO2-max through a 16 week HIIT-training intervention.
We aim to include 40-48 patients with diabetes. They will then undergo baseline-testing consisting of CPET, 15O-PET measures of CBF and MBF, brain MRI, blood sampling (basic health check), cognitive testing (SCIP-D + CANTAB) and echocardiography to rule out significant LV failure.
After that they will be randomixed to either 4 months of twice weekly supervised HIIT-training or a control group that does not train additionally.
After the intervention, the patients will undergo retesting with the same tests from baseline except for brain MR.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diabetes type II diagnose with one of the following:
Non-proliferative diabetic retinopathy
Exclusion Criteria:
Moderate to high intensity training > 1 times/week.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 months of twice weekly supervised HIIT-training on bikes
Other: HIIT-training
Control group who lives on as usual
4 months of twice weekly supervised HIIT-training on indoor bikes.
[15O]H2O PET assessment of the blood perfusion to the brain
Cerebral Blood Perfusion
Time frame: From baseline testing to end of study, 6 months
[15O]H2O PET assessment of the blood perfusion of the heart
Myocardial Blood Perfusion
Time frame: From baseline testing to end of study, 6 months
Cognitive performance (CANTAB)
Testing of a broad range of cognitive functions. The test is tablet based and one of the most used investigator-independent cognitive tests available. The test takes around 45 minutes to perform.
Time frame: From baseline testing to end of study, 6 months
Cognitive Performance (SCIP-D)
Assessed via SCIP-D in order to evaluate a broad range of cognitive areas in around 15-20 minutes. Both groups will undergo both tests. The primary investigator will receive learning in how to carry out the SCIP-D correctly. SCIP-D is a more clinically relevant test that can be used in a clinical setting to identify patients with cognitive dysfunction.
Time frame: From baseline testing to end of study, 6 months
Cardiorespiratory fitness (VO2-max)
Will be assessed as the maximal or peak oxygen consumption (VO2-max or VO2-peak) during a cardiopulmonal exercise test (CPET).
Time frame: From baseline testing to end of study, 6 months
Plan to share: No — Have not gotten the necessary clearence
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.
Of 861 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 29 months is above that.
Counting every sponsor, half of 907 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Bispebjerg and Frederiksberg